Plogosertib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Adenoid Cystic Carcinoma (ACC). According to GlobalData, Phase II drugs for Adenoid Cystic Carcinoma (ACC) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Plogosertib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plogosertib overview
Plogosertib is under development for the treatment of solid tumors including triple negative breast cancer, esophageal cancer, colorectal cancer, Adenoid Cystic Carcinoma (ACC) and blood cancer including chronic lymphoblastic leukemia (CLL), relapsed/refractory leukemias, small-cell lung cancer, non-small cell lung cancer, bladder cancer, hepatocellular carcinoma, metastatic biliary tract cancer, diffuse large b-cell lymphoma, cutaneous t-cell lymphoma, peripheral t-cell lymphomas, ovarian cancer, prostate cancer, cholangiocarcinoma, gall bladder cancer and pancreatic cancer. It is a small molecule administered through oral and intravenous route. It acts by targeting polo-like kinase 1 (Plk1). Polo-like kinases play critical roles during multiple stages of cell cycle progression. Polo-like kinase (PLK) inhibitors targets the mitotic phase of the cell cycle. The drug candidate is based on genomic technology.
It was also under development for myelodysplastic syndrome, relapsed/refractory acute myeloblastic leukemia.
Cyclacel Pharmaceuticals overview
Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company primarily engaged in the development of innovative therapies. These therapies target various phases of cell cycle control for the treatment of cancer and other serious diseases. The company’s major products in development include fadraciclib, a dual inhibitor of cyclin dependent kinases (CDK), and CYC140, a polo-like kinase 1 inhibitor. The company collaborates with renowned cancer research organizations such as MD Anderson Cancer Center and Dana Farber Cancer Institute to enhance its clinical programs. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
For a complete picture of Plogosertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
